Ipsen has welcomed the broader PBS listing of CABOMETYX (cabozantinib) to include a form of advanced kidney cancer. …
Stakeholders welcome broader reimbursement of Ipsen cancer therapy
September 2, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Roche announces historic investment to build US manufacturing base
April 23, 2025 - - Latest News -
'Reflecting the experience of people living with cancer, Pfizer’s new campaign Part of the Story seeks to reshape the narrative'
April 23, 2025 - - Latest News -
US trade agenda looks mostly disinterested in pharmaceuticals
April 23, 2025 - - Latest News -
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 - - Australian Biotech -
Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial
April 22, 2025 - - Australian Biotech -
Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel
April 22, 2025 - - Australian Biotech -
Race says patient enrolment opened at second site for RC220 solid tumour trial
April 22, 2025 - - Australian Biotech